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The bis-phenazine XR5944.14 is a novel cytotoxic agent which intercalates into DNA and inhibits transcription. The objectives of this
study were to determine the dose-limiting toxicity (DLT), the maximum tolerated dose (MTD) and to describe the pharmacokinetics
(PKs) of XR5944.14 when given at doses ranging from 3.6 to 36mgm
 2 every 3 weeks to patients with advanced tumours. Twenty-
seven patients were treated with a total of 77 cycles. Dose-limiting toxicities occurred at doses X24mgm
 2. Oral mucositis was the
most common DLT. Two patients developed acute renal failure possibly related to the study drug. Other less-severe toxicities were
diarrhoea, nausea, vomiting and fatigue. Haematological toxicity was mild. One patient showed an objective partial response.
Pharmacokinetic analysis was performed during the first cycle of treatment and plasma was assayed for XR5944.14 using a validated
liquid chromatography tandem mass spectrometry. The systemic exposure of XR5944.14 increased more than proportionally with
increasing dose, with inter-patient variability increasing from dose level 24mgm
 2 onwards. The lack of correlation between toxicity
and PK values makes it difficult to recommend a dose for further study in phase 2 trials. More work is needed to explain the inter- and
intra-individual variation in PKs and pharmacodynamics.
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Molecularly targeted therapies offer much hope for selected
tumours. However, cytotoxic compounds are still the mainstay
of systemic therapy for most malignancies. There remains a need
for agents with novel mechanisms of action which offer a broad
spectrum of antitumour activity and an improved safety profile
compared with existing anticancer agents.
The bis-phenazine XR5944.14 (MLN 944) is a novel cytotoxic
agent (Figure 1). Initially, it was thought to interfere with the
normal function of topoisomerase I and II (Stewart et al, 2001).
Recent studies, however, have indicated that the agent intercalates
into DNA and inhibits transcription, but has no effect on the
catalytic activity of either topoisomerase I or II (Dai et al, 2004;
Byers et al, 2005). XR5944.14 induces a G(1) and G(2) cell cycle
arrest (Sappal et al, 2004). Agents with this mechanism of action
offer great promise because of their activity against a broad
spectrum of tumour types (Di Nicolantonio et al, 2004).
The efficacy of XR5944.14 is not schedule-dependent, since the
drug is able to kill tumour cells following only a brief exposure. In
studies using murine and human tumour cell lines or xenograft
models, XR5944.14 was exceptionally potent, showing several-fold
greater activity than many common cytotoxic agents such as
doxorubicin, camptothecin, topotecan or paclitaxel and synergy
with carboplatin or doxorubicin (Harris et al, 2005a,b). In nude
mice bearing xenografts of human H69/P SCLC, both partial and
complete regression of large established tumours were seen.
Complete tumour regression was seen at well-tolerated doses of
XR5944. XR5944 even delayed tumour growth in the HT29 human
colon carcinoma, which is relatively refractory to cytotoxic
chemotherapy (Stewart et al, 2001).
Preclinical studies in mice and rats showed that XR5944.14
produced bone marrow suppression and gastrointestinal epithelial
damage. These effects were reversible and recovery was such that
the drug could be given on a 3-weekly cycle. In dogs, prolongation
of the QT-interval, acute urticaria and wheezing were seen, but this
species is particularly sensitive to agents with the potential to cause
histamine release.
In mice, following a single injection of 20mgkg
 1 (60mgm
 2),
the plasma concentration vs time curve was biphasic, with a rapid
decrease in the plasma concentration over the first 10h, followed
by a slower phase of plasma drug elimination with an estimated
half-life of 21h. Pharmacokinetic (PK) studies confirmed that
XR5944.14 has a long elimination half-life and a large volume of
distribution (22.8lkg
 1), which is consistent with the high plasma
protein binding of XR5994. At 168h after dosing [
14C]XR5944.14
in the rat, 70% of the radioactivity was found in the faeces, 10%
appeared in the urine and 20% was in the carcass.
There was a linear relationship between dose and systemic
exposure to XR5944.14. The minimal effect dose of 0.6mgkg
 1 in
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srats was associated with a mean maximum plasma concentra-
tion (Cmax) of 21.7 and 13.8ngml
 1 on days 1 and 22, respectively.
In dogs, the NOEL of 0.2mgkg
 1 (4mgm
 2) was associated
with a mean Cmax of 15.7 and 23.8ngml
 1 on days 1 and 22,
respectively.
The objectives of this phase I study were to determine the
toxicity and the MTD of XR5944 when given as a 30-min infusion
every 3–4 weeks and to describe the PKs of the agent. In addition,
we wanted to document any antitumour activity and to establish
the appropriate dose for phase II studies.
PATIENTS AND METHODS
Patient selection
Eligible patients had histologically confirmed, advanced solid
tumours refractory to standard therapies. They met the following
criteria: aged 18 years or more, ECOG performance status 0 or 1,
expected survival longer than 3 months, recovered from the
reversible effects of prior therapy, with at least 4 weeks since the
last exposure to chemotherapy or radiotherapy and at least 6 weeks
since exposure to nitrosoureas, mitomycin C or antibody therapy,
no more than four previous cytotoxic chemotherapeutic regimens
(including regimens used as adjuvant or neo-adjuvant therapies),
clinically or radiologically evaluable tumours, adequate haemato-
poietic (neutrophil count X1.5 10
9l
 1, platelet count X100 
10
9l
 1, renal (serum creatinine p0.14mmoll
 1) and hepatic
function (bilirubin p1.5 the upper limit of normal (ULN),
aspartate (AST) or alanine transferase (ALT) or alkaline phospha-
tase p twice the ULN). In patients with disease metastatic to the
liver or bone, levels of AST and ALP up to five times the ULN were
allowed. Patients were excluded if they had clinically significant
abnormalities or arrhythmia on 12-lead ECG; had a QTc of more
than 450ms on ECG; had clinical or radiographic evidence of
cerebral metastases; had previous radiotherapy involving X25% of
haematopoietically active bone marrow; had previous high-dose
chemotherapy requiring peripheral blood or bone marrow stem
cell support; if they were taking drugs known to prolong QT
interval. All patients gave written informed consent. The study was
approved by MREC and the institutions’ Local Research Ethics
Committees.
Treatment and dose escalation
XR 5944.14. was supplied by Xenova Ltd as a freeze-dried vial
containing XR5944.14 dimesylate (21.5mg XR5944.14 free base per
vial) and sodium hydroxide/hydrochloric acid. Each vial was
reconstituted with water for injection to give a solution equivalent
to 4mgml
 1 XR5944.14 and the required dose was then added
to a 250-ml (later 500ml) bag of 5% glucose injection BP, which
was stored for up to 4h at 2–81C before use. The drug was
given over 30min using a calibrated infusion pump and a PVC
giving set fitted with an in-line filter. The infusion was repeated
every 3 weeks, with a 1-week delay permissible to allow recovery
from toxicity. A total of six cycles could be given. The starting dose
was 3.6mgm
 2, which was less than 1/10 of the maximum
tolerated dose (MTD) in the rat, and which represented a no
observable adverse effect level in the dog. Dose escalation was
based on the toxicity in the first cycle and followed a standard
modified Fibonacci numerical scheme (Figure 2). Provision was
made in the protocol for intermediate dose levels or expansion of a
dose cohort to define better the dose–toxicity relationship of
XR5944.14. If a patient experienced dose-limiting toxicity (DLT),
the dose of XR5944 was reduced by at least one dose level at
retreatment. Once dose reduction was required, no dose escalation
was permitted. Blood and urine samples were collected for
PK evaluation from each patient following the first infusion of
XR5944.14.
Two patients were entered at each dose level until the
occurrence of either two or more instances of common toxicity
criteria (CTC) (Cancer Therapy Evaluation Programme, 1999)
grade 2 toxicity in which case the cohort was expanded to three
patients, or any CTC grade 3 or higher toxicity, in which case the
cohort was expanded to include up to six patients. If DLT was
observed in 1/3 patients treated at a given dose level, then a further
three patients were added to that dose level. If none of these
additional patients experience DLT (DLT in only 1/6 patients),
then dose escalation resumed. If X2 patients experienced DLT at a
given dose level, then dose escalation ended. Dose-limiting
toxicities were defined as: grade 4 neutropenia lasting for more
than 7 consecutive days; febrile neutropenia; platelets
o25 10
9l
 1; any grade 3 or greater non-haematological toxicity
(except injection site reactions, arthralgias/myalgias, alopecia,
brief fatigue); QTc prolongation 4500ms or clinically significant
arrhythmia during the 24h after infusion of XR5944.14; interval of
more than 35 days between infusions because of toxicities. Second
and subsequent cycles were given providing therapy-related
toxicity had resolved to CTC grade 1 or less, neutrophil count
was X1.5 10
9l
 1, platelets X100 10
9l
 1 and underlying
tumour was stable or had improved.
Treatment assessment
All patients at each dose level were observed for at least 48h
following the first infusion of XR5944.14. They were seen on days
4, 5 and 6 to evaluate possible toxic effects (graded according to
the Common Toxicity Criteria version 2.0) and for further blood
samples and measurement of vital signs. Repeat physical
examination, blood (haematology and chemistry) and urine
samples were done 24h after the infusion and thereafter weekly.
Computerised tomography (CT) scan of the relevant area was done
pretreatment and every two cycles and tumour evaluated using the
RECIST criteria (Therasse et al, 2000). Twelve-lead ECG (before
and 15min, 2, 6 and 24h after the infusion) and 24-h ECG
recording was done after each infusion.
Pharmacokinetic blood and urine sampling
For PK analysis, 5ml blood was drawn from the contralateral arm
to the one used for the drug infusion. The samples were taken
before and 10, 20, 30, 40, 50, 60, 75, 90, 120min, 3, 4, 6, 8, 10, 24,
48, 72, 96 and 120h after the first treatment. Blood samples were
transferred to precooled polystyrene (Teklab, Sacriston, County
Durham, UK) tubes containing lithium heparin then centrifuged at
2500r.p.m for 10min at 41C within 15min of collection. Plasma
was stored frozen at  201C until analysis.
Urine samples for PK analysis were taken 0–2, 2–4 and
8–24h after the first infusion. Two 20ml urine samples
were drawn off and stored at  201C until analysis. Levels of
XR5944.14 were measured by a validated liquid chromatography
tandem mass spectrometry at Huntingdon Life Sciences, Cam-
bridgeshire.
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Figure 1 Molecular structure of XR5944.14.
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sPharmacokinetic data analysis
Actual times at which samples were taken were used throughout.
Values that were below the lower limit of quantification
(o0.1ngml
 1) were entered as 0 in the calculation of the mean.
Maximum plasma concentrations (Cmax) and their time of
occurrence (Tmax) were the observed (measured) values. Areas
under the plasma concentration–time curves up to 8 and 24h
post-dose (AUC0–8 and AUC0–24, respectively) and up to the last
quantifiable sampling time (AUC0–t), were calculated using the
logarithmic trapezoidal rule for declining concentrations and the
linear trapezoidal rule when concentrations increased. The area
Dose  Cycle 1
N = 2
N = 2 N = 2
N = 2 N = 1
N = 1
N = 1 N = 1 N = 1
Cycle 2
Discont.
N = 2
N = 2
N = 3 N = 4 N = 2 N = 2
N = 2 N = 3 N = 4 N = 5
N = 3 N = 3 N = 3 N = 6
N = 7 N = 2 N = 1
N = 1 N = 1
N = 2 N = 2 N = 2 N = 1 N = 1
Discont.
N = 1
Discont.
N = 1
Discont.
N = 1
Discont.
N = 1
Discont.
N = 2
Discont.
N = 2
N = 2 N = 1
Discont.
N = 1
Discont.
N = 2
Discont.
N = 2
Discont.
N = 3
Discont.
N = 1
Discont.
N = 1
Discont.
N = 1
Discont.
N = 1
Discont.
De-escalation
N = 1
Cycle 3 Cycle 4 Cycle 5 Cycle 6
3.6 mg m–2
7.2 mg m–2
14 mg m–2
24 mg m–2
30 mg m–2
33 mg m–2
36 mg m–2
De-escalation N = 1
De-escalation
N = 2
Figure 2 Patient disposition.
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sunder the plasma concentration–time curve extrapolated to
infinity (AUC0–N) was calculated as (AUC0–tþCz/lz), where Cz
is the observed plasma concentration at the time of the last
quantifiable sample and lz is the terminal rate constant. Terminal
rate constants were estimated by fitting a linear regression of log
concentration against time. Terminal half-lives (t1
2) were calculated
as ln 2/lz. Total plasma clearance (CL) was calculated as Dose/
AUC0–N. Volume of distribution during the terminal phase (Vz)
was calculated as Dose/(lz AUC0–N) and volume of distribution
at steady state (Vss) was calculated as CL MRT, where MRT
(mean residence time)¼((AUMC0–N/AUC0–N)) (duration of
infusion/2)). The amount of XR5944.14 excreted unchanged in
urine up to 48h post-dose (Ae0–48) was calculated from the urine
volume and concentration and by summing the amount excreted
in each urine collection. The fraction of the dose excreted
unchanged was calculated as Dose/Ae, and expressed as a
percentage. Renal clearance (CLR) was calculated as Ae0–48/
AUC0–48, where AUC0–48 is the area under plasma concentra-
tion–time curve up to 48h post-dose. The AUC0–48was calculated
from data generated during this study using WinNonlin Pro,
version 3.3 (Pharsight Corporation, Mountain View, CA, USA).
RESULTS
Twenty-seven patients (11 male, 16 female, all Caucasians) with a
median age of 61 (32–79) years were entered from three centres.
All had had previous chemotherapy and nine patients had had
radiotherapy. Two patients each entered the three lowest dose
groups (3.6, 7.2 and 14mgm
 2), and three, five, six and seven
patients were treated with 24, 30, 33 and 36mgm
 2 XR5944.14,
respectively.
In five patients (19%), the dose was de-escalated and patients
were treated further at a lower dose. No intra-patient dose
escalation was planned but one patient received three cycles in the
30mgm
 2 dose group, and after discussion, the dose was escalated
to 33mgm
 2 for cycle 4 again without toxicity but he developed
progressive disease and stopped treatment (Figure 2). Four
patients received the maximum of six cycles. The main reason
for stopping (affecting 13 patients, 57%) was disease progression.
Three patients (13%) discontinued due to a serious adverse event
and three died of progressive disease. Two patients withdrew at
their own request, one patient discontinued at the discretion of the
investigator, and one more patient discontinued due to an adverse
event. Six patients died within 30 days of treatment, four of
progressive disease, one due to subarachnoid haemorrhage
unrelated to XR5944.14 and one with renal failure possibly related
to treatment (see below).
Two patients received cycle 1 at 24mgm
 2, without significant
toxicity, so the next patient was treated with 36mgm
 2, but he
experienced DLT. The next patient was treated with 24mgm
 2
without toxicity making a total of three patients treated at
24mgm
 2 without problems. An intermediate dose of 30mgm
 2
was introduced and three patients received this without DLT. The
dose was then escalated back to 36mgm
 2 for a further four
patients. One of these experienced DLT so two of the five patients
given 36mgm
 2 had documented DLT. A further intermediate
dose of 33mgm
 2 was introduced. Eight patients were enrolled at
this dose level. Six patients in fact received 33mgm
 2, one of
whom experienced DLT. Analysis of the data after the end of the
study showed one patient received in error 37 rather than
33mgm
 2 but without DLT. One patient (patient 9) in fact
received 39mgm
 2 rather than 33mgm
 2 because of an error in
calculation of body surface area and he had DLT. These two
patients have been allocated to the 36mgm
 2 dose level for the
analysis of toxicity as this dose most closely approximates the
actual dose given to these patients. While the study was ongoing
however, it appeared that two of the eight patients allocated
33mgm
 2 dose experienced DLT in cycle 1. The dose was then
de-escalated and the next two patients were enrolled at 30mgm
 2;
both experienced DLT at which point the study was stopped. Dose-
limiting toxicities were seen in nine patients altogether: in cycle 1,
30mgm
 2 – two patients, 33mgm
 2 – one patient, 36mgm
 2 –
two patients; and in cycle 2, 24mgm
 2 – one patient, 30mgm
 2 –
one patient, 36mgm
 2 – one patient; and one patient experienced
DLT at 36mgm
 2 in cycle 1 and at 24mgm
 2 in cycle 2.
Safety analysis
Twenty-seven patients were treated with a total of 77 cycles. Only
toxicities occurring in the first cycle of treatment were considered
in the decision to escalate the dose or expand the number of
patients treated at a given dose level. The highest number of cycles
(18) was given in the 33mgm
 2 group. A total of 12 DLTs were
documented in nine patients, with oral mucositis being most
common (Table 1). Grade 2 toxicity was dose-limiting if the patient
failed to recover to grade 1 or less by day 28. The most common
toxicities encountered were diarrhoea (15 patients), followed by
oral mucositis (14 patients), nausea (13 patients), vomiting (12
patients) and fatigue (12 patients) all of which were more common
at the higher doses (Table 2). Neutropenia was the only toxicity
showing a trend with increasing dose (Table 2). Oral mucositis was
the toxicity most often leading to a serious adverse event (five
patients), followed by diarrhoea (three patients). Three patients
developed renal failure. Nine days after 30mgm
 2, patient 3
developed fever and grade 2 mucositis and diarrhoea. He was
Table 1 Dose-limiting toxicities, Cmax, AUC0–N and action taken
Patient DLT
CTC
grade
Dose
(mgm
 2) Cycle Cmax(ngml
 1)
AUC0–N
(nghml
 1) Action
1 Mucositis 3 24 2 811.78 1010 Dose reduction to 14mgm
 2 after cycle 2
2 Peripheral oedema 2 30 2 3679.84 4280 None
3 Acute renal failure 4 30 1 1782.83 1890 Stopped after cycle 1
4 Acute renal failure 2 30 1 1172.54 1750 Stopped after cycle 1
5 Mucositis 2 33 1 1052.93 1120 Dose reduction to 24mgm
 2 after cycle 1,
stopped after cycle 2
6 Mucositis 2 36 2 2893.06 2220 Dose reduction to 24mgm
 2 after cycle 2
7 Mucositis 3 36 1 1966.00 1630 Dose reduction to 24mgm
 2 with dose-limiting
mucositis again
Neutropenic sepsis 4
8 Mucositis 2 36 1 1799.78 1730 Dose reduction to 30mgm
 2 after cycle 1
9 Mucositis 2 36 1 1070.35 1250 Stopped after cycle 1
Colitis 3
Renal failure 3
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sadmitted the following day, rehydrated with intravenous fluids and
within 24h was apyrexial after tazocin and gentamicin. However,
the serum creatinine had risen to 290mmol. He was given
haemodialysis for 4 days then treatment was stopped at his
request. He died on day 19 with progressive metastatic colon cancer
and renal failure. The relative contribution of XR5944.14 and
gentamicin to the renal failure are unclear. The AUC0–24 was
1450nghml
 1 and the Cmax was1782ngml
 1.P a t i e n t4h a das e r u m
creatinine of 243mmol2daysafter30mgm
 2. Investigations showed
obstructive uropathy. Attempts at ureteric stenting failed and the
patient refused nephrostomies, dying of progressive pulmonary
disease on day 30. Patient 9 was on ibuprofen and, like patient 3,
had a normal serum creatinine at study entry. After 36mgm
 2
(in reality 39mgm
 2), the AUC0–24 was 917nghml
 1 and Cmax
1070ngml
 1. This patient developed acute renal failure associated
with dehydration related to severe mucositis, diarrhoea and colitis
that responded to antibiotics and steroids and he recovered. One
patient developed a severe injection site reaction, which took several
weeks to heal and this patient withdrew from the study. Due to the
unpredictable nature of toxicities, no MTD could be identified.
Overall, the haematological toxicity was mild (Table 2). One
patient in the 36mgm
 2 group had neutropenic sepsis. The patient
recovered and the dose was reduced from 36mgm
 2 to 24mgm
 2
without recurrence. There was no evidence of cumulative toxicity.
The evaluation of ECG or echocardiogram data did not raise
specific safety concerns for XR5944.14 treatment.
Efficacy
One patient developed a partial response according to RECIST
criteria. This 53-year-old patient had progressed during fourth-line
treatment for advanced ovarian cancer before being entered into
the trial. The CT scan after cycle 2 showed a partial response
according to the RECIST criteria. Before the CT scan could be
repeated after 1 month to confirm the response the patient died.
The precise cause of death was unclear. No patients showed a
complete response. None of the patients showed improvements in
performance status in the course of the study.
Pharmacokinetics
Plasma concentration–time profiles of XR5944.14 up to 120h
post-dose were similar for all patients regardless of dose and are
shown in Figure 3. Mean values of the PK parameters are presented
in Table 3. The Cmax, AUC0–t and AUC0–N values increased with
increasing dose, and over the dose range 3.6–14mgm
 2, these
increases appeared to be approximately proportionate to the dose
increment. However, over the dose range 24–36mgm
 2, the
increases were greater than the proportionate dose increment.
Overall, the Cmax and AUC0–t values at the highest dose level
(36mgm
 2) were 1.8-fold higher than those values predicted
from a linear relationship, and there was statistically significant
evidence of non-proportionality (Table 4). Inspection of the
scatterplots of dose vs either AUC0–24 (Figure 4A) or Cmax
(Figure 4B) for XR5944.14 revealed an increase of both parameters
with the dose level administered. The inter-patient variability
increased from dose level 24mgm
 2 onwards. Mean Cmax and
AUC0–24were similar in the higher dose levels. This might explain
the similar toxicity profile seen in the higher dose groups (from
24mgm
 2 onwards). The t1
2, CL (clearance), MRT, apparent
volume of distribution at steady state (Vss) and apparent volume
of distribution during the terminal phase (Vz) tended to decrease
with increasing dose, indicating that the kinetics of XR5944.14
appeared to be nonlinear, and there was statistically significant
Table 2 Worst toxicity per patient according to NCI-CTC version 2.0
Hb Neu WCC Plt Nausea Vomiting Fatigue Diarrhoea Mucositis
Dose
(mgm
 2) N 012340123401234012340123401234012340123401234 D L T
3 . 6 2011002000020000200001100010100110002000020000 0
7 . 2 2011002000020000200001001010010200002000020000 0
1 4 2011001100011000200000010010100011001100020000 0
2 4 3012002001021000210000020011010201002020020010 1
3 0 5041004001041000500003110032000410003110031100 3
3 3 6033004101040200420004110050100312001500015000 1
3 6 7142002004120320430003310034000321102221011410 4
DLT¼dose-limiting toxicity; Hb¼haemoglobin; Neu¼neutrophil; Plt¼platelet; WCC¼total white cell count.
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Figure 3 Mean plasma concentrations of XR5944.14 following a single
intravenous infusion of XR5944.14 (log-linear plot 0–8h).
Table 3 Mean values of the pharmacokinetic parameters
Dose level (mgm
 2)
Parameter 3.6 7.2 14 24 30 33 36
Cmax (ngml
 1) 104.83 268.15 309.21 1300.91 1921.20 1767.86 1951.60
Tmax (h) 0.25 0.25 0.5 0.25
a 0.333
a 0.333
a 0.333
a
AUC0–t (nghml
 1) 105 221 342 987 2050 1780 1780
AUC0–N (nghml
 1) 120 247 374 1050 2160 1740 1870
lz (h
 1) 0.0118 0.0109 0.0115 0.0136 0.0162 0.0111 0.0140
T1
2 (h) 60.6 65.0 61.0 51.1 42.8 62.7 49.6
CL (lh
 1m
 2) 30.0 29.2 37.7 23.3 16.5 20.2 19.4
MRT (h) 37.0 33.0 29.8 25.5 25.0 32.6 21.6
Vz (lm
 2) 2610 2740 3300 1900 1240 2040 1440
Vss (lm
 2) 1090 962 1110 611 428 712 421
AUC¼ area under the concentration–time curve; Cmax¼peak plasma level;
CL¼total plasma clearance; MRT¼mean residence time; Tmax¼time to maximal
concentration; t1
2¼terminal half-life; lz¼terminal rate constant; Vss¼apparent
volume of distribution at steady state; Vz¼apparent volume of distribution during
the terminal phase.
aMedian.
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sevidence of nonlinearity for CL, Vz and Vss (Table 3). The decrease
in CL with increasing dose may indicate that metabolism of
XR5944.14 is saturable, and the decrease in the volume of
distribution may indicate saturation of tissue binding at higher
dose levels.
The urinary excretion of unchanged XR5944.14 was low and in
the range of 0.65–3% of the administered dose, increasing with the
dose over the range 3.6–36mgm
 2. The low urinary excretion of
unchanged XR5944.14 indicates that it is mainly excreted via
another route and suggests that XR5944.14 may undergo extensive
metabolism. There was no correlation between Cmax or AUC0–N
and the occurrence or grade of toxicities (Table 1).
DISCUSSION
This open label, dose-escalation phase I trial describes the first
administration of XR5944. 14 to man. The primary objectives of
the study were to determine the toxicity and the MTD of
XR5944.14 when administered as a 30-min infusion once every 3
to 4 weeks. The most frequently observed toxicities were diarrhoea,
mucositis, nausea and vomiting. Preclinical toxicologic examina-
tion of XR5944.14 had indicated that cardiac enlargement,
prolongation of QTc intervals, allergic reactions and adverse
effects on hepatic function might be expected and patients were
monitored closely for these events. However, an evaluation of the
respective toxicities and laboratory data did not raise specific
safety concerns. Renal function was closely monitored in the study
due to preclinical toxicological findings. No increase in proteinuria
was observed in the study. Renal laboratory variables seemed more
likely to deteriorate in the course of the study than other clinical
chemistry variables, but several of these patients had progressive
pelvic disease potentially contributing to renal dysfunction. Three
patients developed acute renal failure, two of whom had
concomitant mucositis (grades 2 and 3, respectively) and
diarrhoea (grades 2 and 3, respectively) causing dehydration and
in one, gentamicin may have contributed to renal problems.
However, close monitoring for renal function in future adminis-
tration of XR5944.14 to man is warranted.
The lowest dose associated with significant toxicity was
24mgm
 2 and DLTs were observed also in the 30, 33 and
36mgm
 2 dose groups. The maximum dose that could be given
was 36mgm
 2. Although intermediate doses of 30 and 33mgm
 2
were explored, no clear MTD could be identified as the toxicity
patterns proved unpredictable. Half of all DLTs and most dose de-
escalations (three out of five) occurred in the 36mgm
 2 dose
group. Between 30 and 36mgm
 2, an increase in the occurrence of
toxicities was observed, suggesting doses o36mgm
 2 for
potential future studies. Dose vs either AUC0–t or Cmax for
XR5944.14 revealed an increase in both parameters with the dose.
The inter-patient variability increased from dose level 24mgm
 2
onwards. Mean Cmax and AUC0–24were similar in the higher dose
levels. This might explain the similar toxicity profile seen in the
higher dose groups (from 24mgm
 2 onwards) and unpredictable
toxicity patterns in this dose range.
The unpredictability of PKs remains a puzzle. There is a high
level of protein binding with only 0.8% of unbound free drug in
humans at concentrations of XR5944.14 of 100, 500 and
2500ngml
 1. Serum albumin was within normal limits at study
entry in all our patients. The very low metabolic turnover of
[
14C]XR5944.14 by human liver microsomes suggests that clinically
significant in vivo interactions between XR5944.14 and coadminis-
tered drugs which are CYP enzyme inducers or inhibitors, are
unlikely. Although high concentrations of XR5944.14 showed
inhibition of CYPA1/2 and CYP3A4/5, these effects occurred
at concentrations of 10 and 100mM, compared with the highest
Cmax seen in our study of 3679ngml
 1. It is possible that
polymorphisms in drug transporter proteins contributed to the
variation in toxicity seen. The lack of correlation between toxicity
and PK values means that it is difficult to recommend a dose
for further study in phase II trials (Table 1). More work is needed
to explain the intra- and inter-individual variation in drug
handling.
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